Gonadotropin-releasing hormone agonist combined with hormone replacement therapy does not improve the reproductive outcomes of frozen-thawed embryo transfer cycle in elderly patients: a retrospective study

Mei Dong, Li Sun, Li Huang, Yanhong Yi, Xiqian Zhang, Ying Tan, Ge Song, Liling Liu, Fu Wei, Fenghua LiuReproductive 2020 · DOI

TL;DR

This retrospective study investigated whether adding a GnRH agonist to standard hormone replacement therapy (HRT) improves outcomes for elderly women undergoing frozen-thawed embryo transfer (FET). The findings indicate that this combined approach (GnRHa-HRT) does not offer significant reproductive benefits compared to HRT alone in this age group.

What Problem Does This Paper Address?

Frozen-thawed embryo transfer (FET) has become a cornerstone of assisted reproductive technology, offering advantages like increased cumulative pregnancy rates and reduced risks of ovarian hyperstimulation syndrome. However, the optimal protocol for preparing the endometrium for FET, especially in older women, remains an area of active research. Elderly women (defined here as ≥38 years old) face unique challenges due to age-related declines in ovarian function, leading to lower embryo quality and increased chromosomal abnormalities. While traditional hormone replacement therapy (HRT) is a common FET preparation method, researchers have explored combining it with gonadotropin-releasing hormone agonists (GnRH agonists) to suppress luteinizing hormone surges and potentially enhance endometrial receptivity. This study aims to clarify whether this GnRHa-HRT approach offers superior reproductive outcomes for elderly patients compared to standard HRT.

Methods

This was a retrospective cohort study analyzing data from 1264 elderly patients (aged 38 years or older) who underwent their first FET cycle between 2015 and 2017 across three reproductive centers. Patients were divided into two groups based on their endometrial preparation protocol: a traditional hormone replacement therapy (HRT) group and a GnRH agonist combined with hormone replacement therapy (GnRHa-HRT) group. The study meticulously excluded patients who had undergone preimplantation genetic testing, used cryopreserved oocytes or donor oocytes, had insufficient endometrial thickness, or were older than 45. The primary outcome measures included clinical pregnancy rate, ongoing pregnancy rate, live birth rate, and abortion rate. Statistical analysis involved one-way ANOVA, t-tests, and multivariate logistic regression to identify factors influencing reproductive outcomes.

Datasets

The study utilized data from 1264 elderly patients undergoing FET cycles at three reproductive centers between January 2015 and December 2017. This constitutes a retrospective dataset collected from clinical practice. No new benchmarks were introduced.

Key Insights and Ideas

  • GnRHa-HRT offers no clear advantage for elderly patients: The core finding is that adding a GnRH agonist to HRT does not significantly improve key reproductive outcomes like clinical pregnancy, ongoing pregnancy, live birth, or abortion rates in older women undergoing FET.
  • Age and embryo quality are paramount: The study reinforces that patient age and the quality of the transferred embryos (specifically, blastocyst stage vs. cleavage stage) are significant determinants of FET success, even more so than the chosen endometrial preparation protocol in this age group.
  • Number of embryos transferred matters: Transferring more embryos, up to a certain point, was associated with improved live birth and reduced abortion rates, highlighting a trade-off that clinicians and patients must consider.
  • Endometrial thickness threshold: The study used a relatively strict threshold of 8 mm for endometrial thickness, which is consistent with some literature suggesting this is a good indicator for successful FET.

Key Results

  • Initial analysis showed concerning trends for GnRHa-HRT: While initial comparisons showed no significant difference in clinical or ongoing pregnancy rates, the GnRHa-HRT group exhibited a lower live birth rate (17.54% vs. 24.10%) and a higher abortion rate (45.56% vs. 32.97%) compared to the HRT group.
  • Multivariate analysis corrects the picture: Crucially, after adjusting for confounding factors using multivariate analysis, these differences in live birth and abortion rates between the GnRHa-HRT and HRT groups became statistically insignificant (p = 0.1333 for live birth, p = 0.1881 for abortion). This suggests the initial observed differences were likely due to other underlying patient characteristics.
  • Significant predictors of outcome: Multivariate analysis identified patient age and the number of embryos transferred as significant factors affecting both live birth and abortion rates. Antral follicle count (AFC) was also a significant predictor of live birth rate. Blastocyst transfers were associated with a higher live birth rate compared to cleavage-stage embryos.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective design: The study's retrospective nature means it cannot establish causality and is subject to biases inherent in observational data. A randomized controlled trial would be ideal.
  • Limited follow-up: Patients were only followed up for 12 weeks, preventing the assessment of later obstetric outcomes like preterm birth.
  • Small GnRHa-HRT group: The GnRHa-HRT group was significantly smaller than the HRT group, which could limit the statistical power to detect subtle differences. This size difference is attributed to physician preference.
  • No uniform luteal support: The lack of a standardized luteal support regimen, while potentially reflecting real-world practice, could introduce variability.

Future work should focus on well-designed prospective clinical trials comparing various FET programs, including natural cycle and modified natural cycle approaches. Further research into endometrial transcriptome testing and molecular mechanisms of endometrial function could also refine personalized treatment strategies. Stricter obstetric follow-up in future studies is also recommended.

Summary updated

Abstract

A GnRH agonist combined with hormone replacement therapy did not improve the reproductive outcomes of frozen-thawed embryo cycles in elderly patients.
BibTeX
@inproceedings{dong2020gonadotropin,
  author = {Mei Dong and Li Sun and Li Huang and Yanhong Yi and Xiqian Zhang and Ying Tan and Ge Song and Liling Liu and Fu Wei and Fenghua Liu},
  title = {{Gonadotropin-releasing hormone agonist combined with hormone replacement therapy does not improve the reproductive outcomes of frozen-thawed embryo transfer cycle in elderly patients: a retrospective study}},
  booktitle = {Reproductive},
  year = {2020},
  doi = {10.1186/s12958-020-00626-8},
}
Figure